The development of multiple reaction monitoring assays for liver-derived plasma proteins

Proteomics - Clinical Applications

Volumn 1, Issue 12, 2007, Pages 1570-1581

  McKay, Matthew J ^a   Sherman, Jamie ^a   Laver, Matthew T ^a   Baker, Mark S ^a   Clarke, Stephen J ^b   Molloy, Mark P ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Biomarker; Colorectal cancer; Multiple reaction monitoring (MRM); Quantitation; Tandem mass spectrometry

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE; PLASMA PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; COLORECTAL CANCER; CONTROLLED STUDY; DATA ANALYSIS; DRUG MONITORING; HUMAN; LIVER; MALE; MULTIPLE REACTION MONITORING ASSAY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; QUANTITATIVE ASSAY; REPRODUCIBILITY;

EID: 38349133699     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200700305     Document Type: Article

References (31)

1. Anderson, N. L., Anderson, N. G., The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
2. Anderson, N. L., Anderson, N. G., The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2003, 2, 50.
3. Anderson, N. L., Polanski, M., Pieper, R., Gatlin, T. et al., The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 2004, 3, 311-326.
4. Colburn, W. A., Biomarkers in drug discovery and development: From target identification through drug marketing. J. Clin. Pharmacol. 2003, 43, 329-341.
5. Frank, R., Hargreaves, R., Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2, 566-580.
6. Stoughton, R. B., Friend, S. H., How molecular profiling could revolutionize drug discovery. Nat Rev. Drug Discov. 2005, 4, 345-350.
7. Li, A. C., Alton, D., Bryant, M. S., Shou, W. Z., Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a QTrap instrument. Rapid Commun. Mass Spectrom. 2005, 19, 1943-1950.
8. Poon, G. K., Kwei, G., Wang, R., Lyons, K. et al., Integrating qualitative and quantitative liquid chromatography/tandem mass spectrometric analysis to support drug discovery. Rapid Commun. Mass Spectrom. 1999, 13, 1943-1950.
9. Zhang, F., Bartels, M. J., Stott, W. T., Quantitation of human glutathione S-transferases in complex matrices by liquid chromatography/ tandem mass spectrometry with signature peptides. Rapid Commun. Mass Spectrom. 2004,18, 491-498.
10. 13C-labeled peptide standards. Proteomics 2004, 4, 1175-1186.
11. Unwin, R. D., Griffiths, J. R., Leverentz, M. K., Grallert, A. et al., Multiple reaction monitoring to identify sites of protein phosphorylation with high sensitivity. Mol. Cell. Proteomics 2005, 4, 1134-1144.
12. Cox, D. M., Zhong, F., Du, M., Duchoslav, E. et al., Multiple reaction monitoring as a method for identifying protein posttranslational modifications. J. Biomol. Technol. 2005, 16, 83-90.
13. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573-88.
14. Melanson, J. E., Chisholm, K. A., Pinto, D. M., Targeted comparative proteomics by liquid chromatography/matrix-assisted laser desorption/ ionization triple-quadrupole mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 904-910.
15. Ciccimaro, E., Hevko, J., Blair, I. A., Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/ multiple reaction monitoring mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 3681-3692.
16. Patil, S. T., Higgs, R. E., Brandt, J. E., Knierman, M. D. et al., Identifying pharmacodynamic protein markers of centrally active drugs in humans: A pilot study in a novel clinical model. J. Proteome Res. 2007, 6, 955-966.
17. Lin, S., Shaler, T. A., Becker, C. H., Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap. Anal. Chem. 2006, 78, 5762-5767.
18. Hopfgartner, G., Varesio, E., Tschappat, V., Grivet, C. et al., Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules. J. Mass Spectrom. 2004, 39, 845-855.
19. Barr, J. R., Maggio, V. L., Patterson, D. G., Jr., Cooper, G. R. et al., Isotope dilution-mass spectrometric quantification of specific proteins: Model application with apolipoprotein A-I. Clin. Chem. 1996, 42, 1676-1682.
20. Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M. et al., Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000, 355, 1041-1047.
21. Chiou, W. L., Jeong, H. Y., Wu, T. C., Ma, C., Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin. Pharmacol. Ther. 2001, 70, 305-310.
22. Masica, A. L., Mayo, G., Wilkinson, G. R., In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin. Pharmacol. Ther. 2004, 76, 41-49.
23. Galteau, M. M., Shamsa, F., Urinary 6-beta-hydroxycortisol; a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol. 2003, 59, 713-733.
24. Rivory, L. P., Slaviero, K. A., Clarke, S. J., Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer 2002, 87, 277-280.
25. Slaviero, K. A., Clarke, S. J., Rivory, L. P., Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 2003, 4, 224-232.
26. Yang, F., Brune, J. L., Baldwin, W. D., Barnett, D. R., Bowman, B. H., Identification and characterization of human haptoglobin cDNA. Proc. Natl. Acad. Sci. USA 1983, 80, 5875-5879.
27. van der Straten, A., Herzog, A., Jacobs, P., Cabezon, T., Bollen, A., Molecular cloning of human haptoglobin cDNA: Evidence for a single mRNA coding for alpha 2 and beta chains. EMBO J. 1983, 2, 1003-1007.
28. Alexandre, J., Rey, E., Girre, V., Grabar, S. et al., Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: A prospective study. Ann. Oncol. 2007, 18, 168-172.
29. Charles, K. A., Rivory, L. P., Brown, S. L., Liddle, C. et al., Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin. Cancer Res. 2006, 12, 7492-7497.
30. Corzett, T. H., Fodor, I. K., Choi, M. W., Walsworth, V. L. et al., Statistical analysis of the experimental variation in the proteomic characterization of human plasma by two-dimensional difference gel electrophoresis. J. Proteome Res. 2006, 5, 2611-2619.
31. Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie, D. B. et al., Massspectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 2004, 3, 235-244.